SCHEMBL3901133

SCHEMBL3901133

NC(=O)N([C@@H]1CCNC1)[C@@H]1CCNC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 11/20 0.41
SLC6A4 P31645 11/20 0.41
SLC6A3 Q01959 6/20 0.41
CYP2D6 P10635 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.41
KCNH2 Q12809 3/20 0.40
SLC6A1 P30531 2/20 0.36
GABRA5 P31644 2/20 0.36
GABRB2 P47870 2/20 0.36
SLC6A12 P48065 2/20 0.36
SLC6A11 P48066 2/20 0.36
SLC6A13 Q9NSD5 2/20 0.36
GABRA1 P14867 1/20 0.36
GABRR1 P24046 1/20 0.36
GABRA4 P48169 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21798770 0.88 CYP2D6 (0.52) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
SCHEMBL4197278 0.86 GABRA1 (0.41) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
SCHEMBL27624686 0.79 SLC6A4 (0.42) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
SCHEMBL28337720 0.79 SLC6A4 (0.47) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
SCHEMBL27905543 0.77 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL5023299 0.77 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL27905533 0.77 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL25306928 0.75 SLC6A4 (0.49) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL4167603 0.75 SLC6A4 (0.49) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL27957684 0.75 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2018381-A2 USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS Novartis AG (CH) 2009-01-28 EP disclosed
EP-2012759-A1 PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS Novartis AG (CH) 2009-01-14 EP disclosed
EP-1861412-A1 ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY Novartis AG (CH) 2007-12-05 EP disclosed
WO-2007121923-A1 PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2007-11-01 WO disclosed
WO-2007121918-A2 USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2007-11-01 WO disclosed
WO-2006097260-A1 ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY NOVARTIS AG (CH) 2006-09-21 WO disclosed